HealthLeaders Media March 26, 2024
Marie DeFreitas

Some states are hesitant to cover the popular drugs.

Weight loss drugs have soared in popularity; while some states have been hesitant to cover them, others have not. A recent JAMA study found that five states offer unrestricted coverage of GLP-1 drugs Wegovy and Saxenda that were approved for weight loss.

The data from this study comes from formularies for 47 state Medicaid programs from the first quarter of 2023.

The study found that a total of ten states cover Saxenda or Wegovy for weight loss, while five of those states offered restricted access through...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicaid, Patient / Consumer, Pharma / Biotech, Provider, States, Survey / Study, Trends
Related Articles:
Georgia Medicaid shakeup could force 3 in 4 beneficiaries to change plans: Centene CEO
Providence’s Joint Venture With Compassus Likely Delayed Amid Concerns About Patient Care And Rural Access
Multisector Plan for Aging Learning Collaborative
CMS taps 4 states for behavioral innovation model: 5 things to know
UCSD Health, county end plans for behavioral health hub

Share This Article